DeGregorio M W, Carrera C J, Klock J C, Pegelow C H, Wilbur J R
Cancer Treat Rep. 1982 Dec;66(12):2085-8.
Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: regimen A-an iv bolus dose of 50 mg/m2, and regimen B-a loading dose of 15 mg/m2 followed by 35 mg/m2 infused over 4 hours. Peak plasma levels were four times higher after regimen A the B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.
在一名急性淋巴细胞白血病患者中，通过两种不同方案给药后，连续检测柔红霉素的白血病细胞和血浆浓度：方案A——静脉推注剂量为50mg/m²，方案B——负荷剂量为15mg/m²，随后在4小时内输注35mg/m²。方案A后的血浆峰值水平是方案B后的四倍，而白血病细胞浓度无显著差异。两种给药方法后的急性毒性或治疗效果均未见差异。然而，我们已经证明，通过持续输注可以降低柔红霉素的血浆峰值水平，而不会显著改变靶组织浓度。
